The kinase inhibitory region of SOCS-1 is sufficient to inhibit T-helper 17 and other immune functions in experimental allergic encephalomyelitis

Journal of Neuroimmunology

Volumn 232, Issue 1-2, 2011, Pages 108-118

  Jager, Lindsey D ^a   Dabelic, Rea ^a   Waiboci, Lilian W ^a   Lau, Kenneth ^a   Haider, Mohammad S ^a   Ahmed, Chulbul M I ^a   Larkin, Joseph ^a   David, Samuel ^b   Johnson, Howard M ^a  

^a UNIVERSITY OF FLORIDA   (United States)

^b RESEARCH INSTITUTE OF THE MCGILL UNIVERSITY HEALTH CENTRE   (Canada)

Author keywords

Experimental allergic encephalomyelitis; Mimetic peptide; Multiple sclerosis; Suppressors of cytokine signaling

Indexed keywords

GAMMA INTERFERON; INTERLEUKIN 17; INTERLEUKIN 23; JANUS KINASE 2; MESSENGER RNA; MYELIN BASIC PROTEIN; PROTEIN KINASE TYK2; STAT3 PROTEIN; SUPPRESSOR OF CYTOKINE SIGNALING 1; SUPPRESSOR OF CYTOKINE SIGNALING 1 KINASE INHIBITORY REGION; SUPPRESSOR OF CYTOKINE SIGNALING 3; TOLL LIKE RECEPTOR; UNCLASSIFIED DRUG;

ALLERGIC ENCEPHALOMYELITIS; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CD4+ T LYMPHOCYTE; CELL DIFFERENTIATION; CELL INFILTRATION; CELL PROLIFERATION; CONTROLLED STUDY; DISEASE SEVERITY; DRUG EFFICACY; DRUG INHIBITION; ENZYME ACTIVATION; ENZYME ACTIVITY; FEMALE; IMMUNE RESPONSE; IMMUNIZATION; LYMPHOCYTE PROLIFERATION; MACROPHAGE ACTIVATION; MOUSE; MULTIPLE SCLEROSIS; NONHUMAN; OUTCOME ASSESSMENT; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN EXPRESSION; PROTEIN INTERACTION; PROTEIN SYNTHESIS INHIBITION; REAL TIME POLYMERASE CHAIN REACTION; SPLEEN CELL; TH17 CELL;

ANIMALS; BLOTTING, WESTERN; ENCEPHALOMYELITIS, AUTOIMMUNE, EXPERIMENTAL; INTERFERON-GAMMA; INTERLEUKIN-17; MICE; PEPTIDES; PROTEIN KINASE INHIBITORS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; SIGNAL TRANSDUCTION; SUPPRESSOR OF CYTOKINE SIGNALING PROTEINS; TH17 CELLS;

EID: 79952246179     PISSN: 01655728     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jneuroim.2010.10.018     Document Type: Article

References (41)

1. Abbott N.J., Patabendige A.A.K., Dolman D.E.M., Yusof S.R., Begey D.J. Structure and function of the blood-brain barrier. Neurobiol. Dis. 2010, 37:13-25.
2. Abromson-Leeman S., Bronson R.T., Dorf M.E. Encephalitogenic T cells that stably express both T-bet and RORγt consistently produce IFNγ but have a spectrum of IL-17 profiles. J. Neuroimmunol. 2009, 215:10-24.
3. Ahmed C.M., Dabelic R., Waiboci L.W., Jager L.D., Heron L.L., Johnson H.M. SOCS-1 mimetics protect mice against lethal poxvirus infection: identification of a novel endogenous antiviral system. J. Virol. 2009, 83:1402-1415.
4. Alexander W.S., Hilton D.J. The role of suppressors of cytokine signaling (SOCS) proteins in regulation of the immune response. Annu. Rev. Immunol. 2004, 22:503-529.
5. Babon J.J., Sabo J.K., Zhang J.G., Nicola N.A., Norton R.S. The SOCS box encodes a hierarchy of affinities for cullin5: implications for ubiquitin ligase formation and cytokine signaling suppression. J. Mol. Biol. 2009, 387:162-174.
6. Berard J.L., Kerr B.J., Johnson H.M., Davis S. Differential expression of SOCS1 in macrophages in relapsing-remitting and chronic EAE and its role in disease severity. Glia 2010, 58:1816-1826.
7. Boniface K., Blom B., Liu Y.J., de Waal Malefyt R. From interleukin-23 to T-helper 17 cells: human T-helper cell differentiation revisited. Immunol. Rev. 2008, 226:132-146.
8. Cayrol R., Wosik K., Berard J.L., Dodelet-Devillers A., Ifergan I., Kebir H., Haqqani A.S., Kreymborg K., Krug S., Moumdjian R., Bouthillier A., Becher B., Arbour N., David S., Stanimirovic D., Prat A. Activated leukocyte cell adhesion molecule promotes leukocyte trafficking into the central nervous system. Nat. Immunol. 2008, 9:137-145.
9. Croker B.A., Kiu H., Nicholson S.E. SOCS regulation of the JAK/STAT signaling pathway. Semin. Cell Dev. Biol. 2008, 19:414-422.
10. Dalpke A., Heeg K., Bartz H., Baetz A. Regulation of innate immunity by suppressor of cytokine signaling proteins. Immunobiology 2008, 213:225-235.
11. DiGiandomenico A., Wylezinski L.S., Hawiger J. Intracellular delivery of a cell-penetrating SOCS1 that targets IFNγ signaling. Sci. Signal. 2009, 2:1-10.
12. El Behi M., Dubucquoi S., Lefranc D., Zephir H., De Seze J., Vermersch P., Prin L. New insights into cell responses involved in experimental autoimmune encephalomyelitis and multiple sclerosis. Immunol. Lett. 2005, 96:11-26.
13. El Behi M., Rostami A., Ciric B. Current views on the roles of Th1 and Th17 cells in experimental autoimmune encephalomyelitis. J. Neuroimmune Pharmacol 2010, 5:189-197.
14. Ercolini A.M., Miller S.D. Mechanisms of immunopathology in murine models of central nervous system demyelinating disease. J. Immunol. 2006, 176:3293-3298.
15. Farez M.F., Quintana F.J., Gandhi R., Izquierdo G., Lucas M., Weiner H.L. Toll-like receptor 2 and poly(ADP-ribose) polymerase 1 promote central nervous system neuroinflammation in progressive EAE. Nat. Immunol. 2009, 10:958-964.
16. Fitzgerald K.A., Palsson-McDermott E.M., Bowie A.G., Jefferies C.A., Mansell A.S., Brady G., Brint E., Dunne A., Gray P., Harte M.T., McMurray D., Smith D.E., Sims J.E., Bird T.A., O'Neill L.A. Mal (MyD88-adapter-like) is required for Toll-like receptor-4 signal transduction. Nature 2001, 413:78-83.
17. Fletcher T.C., DiGiandomenico A., Hawiger J. Extended anti-inflammatory action of a degradation-resistant mutant of cell-penetrating suppressor of cytokine signaling 3. J. Biol. Chem. 2010, 285:18727-18736.
18. Flowers L.O., Johnson H.M., Mujtaba M.G., Ellis R., Haider S.M., Subramaniam P.S. Characterization of a peptide inhibitor of Janus kinase 2 that mimics suppressor of cytokine signaling 1 function. J. Immunol. 2004, 172:7510-7518.
19. Flowers L.O., Subramaniam P.S., Johnson H.M. A SOCS-1 peptide mimetic inhibits both constitutive and IL-6 induced activation of STAT3 in prostate cancer cells. Oncogene 2005, 24:2114-2220.
20. Javed A., Reder A.T. Therapeutic role of beta-interferons in multiple sclerosis. Pharmacol. Ther. 2006, 110:35-56.
21. Jo D., Liu D., Yao S., Collins R.D., Hawiger J. Intracellular therapy with SOCS3 inhibits inflammation and apoptosis. Nat. Med. 2005, 11:892-898.
22. Kebir H., Ifegan I., Alvarez J.I., Bernard M., Pourier J., Arbour N., Duquette P., Prat A. Preferential recruitment of interferonγ-expressing Th17 cells in multiple sclerosis. Ann. Neurol. 2009, 66:390-402.
23. Kobayashi T., Takaesu G., Yoshimura A. Mal-function of TLRs by SOCS. Nat. Immunol. 2006, 7:123-124.
24. Korn T., Bettelli E., Oukka M., Kuchroo V.K. IL-17 and Th17 cells. Annu. Rev. Immunol. 2009, 27:485-517.
25. Kyte J., Doolittle R.F. A simple method for displaying the hydropathic character of a protein. J. Mol. Biol. 1982, 157:105-132.
26. Lassmann H., Bruck W., Lucchinetti C.F. The immunopathology of multiple sclerosis: an overview. Brain Pathol. 2007, 17:210-218.
27. Linker R.A., Lee D.H. Models of autoimmune demyelination in the central nervous system: on the way to translational medicine. Exp. Transl. Stroke Med 2009, 10.1186/2040-7378-1-5.
28. Mansell A., Smith R., Doyle S.L., Gray P., Fenner J.E., Crack P.J., Nicholson S.E., Hilton D.J., O'Neill L.A., Hertzog P.A. Suppressor of cytokine signaling 1 negatively regulates Toll-like receptor signaling by mediating Mal degradation. Nat. Immunol. 2006, 7:148-155.
29. Marta M., Meier U.C., Lobell A. Regulation of autoimmune encephalomyelitis by toll-like receptors. Autoimmun. Rev. 2009, 8:506-509.
30. McGeachy M.J., Chen Y., Tato C.M., Laurence A., Joyce-Shaikh B., Blumenschein W.M., McClanahan T.K., O'Shea J.J., Cua D.J. The interleukin-23 receptor is essential for the terminal differentiation of interleukin-17-producing effector T helper cells in vivo. Nat. Immunol. 2009, 10:314-324.
31. Mujtaba M.G., Flowers L.O., Patel C.B., Patel R.A., Haider M.I., Johnson H.M. Treatment of mice with the suppressor of cytokine signaling-1 mimetic peptide, tyrosine kinase inhibitor peptide, prevents development of the acute form of experimental allergic encephalomyelitis and induces stable remission in the chronic relapsing/remitting form. J. Immunol. 2005, 175:5077-5086.
32. Oukka M. Interplay between pathogenic Th17 and regulatory T cells. Ann. Rheum. Dis. 2007, 66:iii87-iii90.
33. Qin H., Niyongere S.A., Lee S.J., Baker B.J., Benveniste E.N. Expression and functional significance of SOCS-1 and SOCS-3 in astrocytes. J. Immunol. 2008, 181:3167-3176.
34. Stuve O. Knowns and unknowns in the future of multiple sclerosis treatment. J. Neurol. Sci. 2009, 287:S30-S36.
35. Szente B.E., Soos J.M., Johnson H.M. The C-terminus of IFNγ is sufficient for intracellular function. Biochem. Biophys. Res. Commun. 1994, 203:1645-1654.
36. Takahashi Y., Kaneda H., Takasuka N., Hattori K., Nishikawa M., Takakura Y. Enhancement of antiproliferative activity of interferons by RNA interference-mediated silencing of SOCS gene expression in tumor cells. Cancer Sci. 2008, 99:1650-1655.
37. Tanaka K., Ichiyama K., Hashimoto M., Yoshida H., Takimoto T., Takaesu G., Torisu T., Hanada T., Yasukawa H., Fukuyama S., Inoue H., Nakanishi Y., Kobayashi T., Yoshimura A. Loss of suppressor of cytokine signaling 1 in helper T cells leads to defective Th17 differentiation by enhancing antagonistic effects of IFNγ on STAT3 and Smads. J. Immunol. 2008, 180:3746-3756.
38. Thiam K., Long E., Verwaerde C., Auriault C., Gras-Masse H. IFNγ-derived lipopeptide: influence of lipid modification on the conformation and the ability to induce MHC class II expression on murine and human cells. J. Med. Chem. 1999, 42:3732-3736.
39. Waiboci L.W., Ahmed C.M., Mujtaba M.G., Flowers L.O., Martin J.P., Haider M.I., Johnson H.M. Both the suppressor of cytokine signaling-1 (SOCS-1) kinase inhibitory region and SOCS-1 mimetic bind to JAK2 autophosphorylation site: implications for the development of a SOCS-1 antagonist. J. Immunol. 2007, 178:5058-5068.
40. Yasukawa H., Misawa H., Sakamoto H., Masuhara M., Sasaki A., Wakioka T., Ohtsuka S., Imaizumi T., Matsuda T., Ihle J.N., Yoshimura A. The JAK-binding protein JAB inhibits Janus tyrosine kinase activity through binding in the activation loop. EMBO J. 1999, 18:1309-1320.
41. Yoshimura A., Naka T., Kubo M. SOCS proteins, cytokine signaling and immune regulation. Nat. Rev. Immunol. 2007, 7:454-465.